Epstein–Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed–Sternberg cells via the PI3K-AKT-mTOR pathway

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Diagnosis of Hodgkin lymphoma in the modern era

(2018) Hao-Wei Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Disruption of direct 3D telomere–TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed–Sternberg cells

(2017) Hans Knecht et al.   LABORATORY INVESTIGATION

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

(2017) Atif Ali Hashmi et al.   World Journal of Surgical Oncology

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

(2016) Donatella Aldinucci et al.   CANCER LETTERS

CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth

(2016) Sakthi Rajendran et al.   OncoImmunology

LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates

(2015) V. Lajoie et al.   BLOOD

Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation

(2015) Zhe Shao et al.   JOURNAL OF LEUKOCYTE BIOLOGY

High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis

(2015) Ewelina Grywalska et al.   PLoS One

Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival

(2015) Carlo Visco et al.   Oncotarget

CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses

(2015) Bhushan Dharmadhikari et al.   OncoImmunology

EBV May Be Expressed in the LP Cells of Nodular Lymphocyte–predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults

(2014) Alison R. Huppmann et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

(2014) Dass S. Vinay et al.   BMB Reports

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals

(2014) Mayumi Yoshimori et al.   PLoS One

CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas

(2012) Matthew W. Anderson et al.   AMERICAN JOURNAL OF PATHOLOGY

Expression of CD137 on Hodgkin and Reed-Sternberg Cells Inhibits T-cell Activation by Eliminating CD137 Ligand Expression

(2012) W. T. Ho et al.   CANCER RESEARCH

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia

(2012) Ines M. Macias-Perez et al.   Current Hematologic Malignancy Reports

PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

(2011) D. A. Fruman et al.   Cancer Discovery

CD137, implications in immunity and potential for therapy

(2009) Elaine Thum   Frontiers in Bioscience-Landmark

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

(2009) Chao Wang et al.   IMMUNOLOGICAL REVIEWS